1
|
Marçais C, Chetioui A, Yordanov Y, Reuter PG, Raynal PA, Pateron D, Thiebaud PC. Quels médicaments dans nos services mobiles d’urgence et de réanimation ? Ann Fr Med Urgence 2019. [DOI: 10.3166/afmu-2019-0123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Introduction : La dotation médicamenteuse nécessaire lors d’une intervention médicale préhospitalière n’est pas référencée, ce qui laisse chaque structure libre de constituer sa propre pharmacie. L’objectif principal de notre étude était de faire un état des lieux des dotations médicamenteuses des services mobiles d’urgence et de réanimation (Smur).
Méthode : Il s’agit d’une étude observationnelle déclarative, réalisée entre novembre 2017 et avril 2018 auprès de l’ensemble des Smur adultes de France.
Résultats : Sur 402 services sollicités, 191 (48 %) ont répondu et 177 (44 %) inclus. Un Smur disposait en moyenne de 74 ± 9 médicaments. Au total, 231 molécules ont été répertoriées. Parmi elles, 73 (32%) étaient disponibles dans plus de 50%des structures et 94 (41%) dans moins de 5%. Il existait des disparités des dotations médicamenteuses dans l’ensemble des spécialités, plus ou moins importantes selon la classe thérapeutique.
Discussion : La majorité des services dispose des médicaments nécessaires à la prise en charge des urgences les plus graves. Cependant, quelques recommandations ne sont pas toujours respectées. À la vue de nos résultats et des recommandations en vigueur, nous proposons une liste de molécules qui nous semblent être indispensables dans l’arsenal thérapeutique des Smur.
Collapse
|
2
|
Marmontel O, Charrière S, Simonet T, Bonnet V, Dumont S, Mahl M, Jacobs C, Nony S, Chabane K, Bozon D, Janin A, Peretti N, Lachaux A, Bardel C, Millat G, Moulin P, Marçais C, Di Filippo M. Single, short in-del, and copy number variations detection in monogenic dyslipidemia using a next-generation sequencing strategy. Clin Genet 2018; 94:132-140. [DOI: 10.1111/cge.13250] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Revised: 03/12/2018] [Accepted: 03/14/2018] [Indexed: 01/08/2023]
Affiliation(s)
- O. Marmontel
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
| | - S. Charrière
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE; Hospices Civils de Lyon; Bron France
| | - T. Simonet
- Service de Biostatistique-Bioinformatique; Hospices Civils de Lyon; Lyon France
- Univ Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR5558; Villeurbanne France
| | - V. Bonnet
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - S. Dumont
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - M. Mahl
- Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, GHS; Hospices Civils de Lyon; Pierre-Benite France
| | - C. Jacobs
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - S. Nony
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
| | - K. Chabane
- Laboratoire d'hématologie, Biologie Moléculaire; Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon; Pierre-Benite France
| | - D. Bozon
- Plateforme NGS CHU Lyon, GHE; Hospices Civils de Lyon; Bron France
| | - A. Janin
- Plateforme NGS CHU Lyon, GHE; Hospices Civils de Lyon; Bron France
| | - N. Peretti
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE; Hospices Civils de Lyon; Bron France
| | - A. Lachaux
- Service de Gastroentérologie Hépatologie et Nutrition Pédiatrique, GHE; Hospices Civils de Lyon; Bron France
- INSERM U 1111, Faculté de médecine Lyon Est; Université Lyon 1; Lyon France
| | - C. Bardel
- Service de Biostatistique-Bioinformatique; Hospices Civils de Lyon; Lyon France
- Univ Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR5558; Villeurbanne France
| | - G. Millat
- Plateforme NGS CHU Lyon, GHE; Hospices Civils de Lyon; Bron France
| | - P. Moulin
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, GHE; Hospices Civils de Lyon; Bron France
| | - C. Marçais
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
- Centre de Biologie Sud, Laboratoire de Biochimie moléculaire et métabolique, GHS; Hospices Civils de Lyon; Pierre-Benite France
- CENS, Centre de Recherche en Nutrition Humaine Rhône-Alpes; Oullins France
| | - M. Di Filippo
- Service de Biochimie et Biologie moléculaire Grand Est, GHE; Hospices Civils de Lyon; Bron France
- Univ-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397; Université Claude Bernard Lyon 1, INSA Lyon; Villeurbanne France
| |
Collapse
|
3
|
Luce M, Marçais C, Maucort-Boulch D, Drai J, Jean G, Fouque D. Impact des variants génétiques de Klotho sur le taux circulant de Klotho et la morbi-mortalité cardiovasculaire chez les patients insuffisants rénaux chroniques dialysés. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Caussy C, Charrière S, Dallongeville J, Lefai E, Euthine V, Delay M, Meirhaeghe A, Di Filippo M, Rome S, Moulin P, Marçais C. A TG-associated minor LPL haplotype supresses miR-29 binding on LPL 3'UTR. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Charriere S, Peretti N, Bernard S, Charcosset M, Sassolas A, Lachaux A, Moulin P, Marçais C. 42 IDENTIFICATION OF TWO NEW MUTATIONS OF GPIHBP1 IN SEVERE HYPERCHYLOMICRONEMIA. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70043-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Charrière S, Cugnet C, Guitard M, Bernard S, Groisne L, Charcosset M, Pruneta-Deloche V, Merlin M, Billon S, Delay M, Sassolas A, Moulin P, Marçais C. Modulation of phenotypic expression of APOA5 Q97X and L242P mutations. Atherosclerosis 2009; 207:150-6. [DOI: 10.1016/j.atherosclerosis.2009.04.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2008] [Revised: 04/07/2009] [Accepted: 04/14/2009] [Indexed: 12/26/2022]
|
7
|
Pittis MG, Ricci V, Guerci VI, Marçais C, Ciana G, Dardis A, Gerin F, Stroppiano M, Vanier MT, Filocamo M, Bembi B. Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in-frame start codon. Hum Mutat 2004; 24:186-7. [PMID: 15241805 DOI: 10.1002/humu.9263] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Niemann Pick disease (NPD) is an autosomal recessive disorder due to the deficit of lysosomal acid sphingomyelinase, which results in intracellular accumulation of sphingomyelin. In the present work we studied 18 patients with NPD type B, including five individuals who presented an intermediate phenotype characterised by different levels of neurological involvement. We identified nine novel mutations in the SMPD1 gene including six single base changes c.2T>G, c.96G>A, c.308T>C, c.674T>C, c.732G>C, c.841G>A (p.M1_W32del, p.W32X, p.L103P, p.L225P, p.W244C, p.A281T) and three frameshift mutations c.100delC, c.565dupC, c.575dupC (p.G34fsX42, p.P189fsX1 and p.P192fsX14). The novel c.2T>G (p.M1_W32del) mutation inactivates the first in-frame translation start site of the SMPD1 gene and in the homozygous status causes NPD type B indicating that in'vivo translation of wild type SMPD1 initiates from the first in-frame ATG. Moreover, the new c.96G>A (p.W32X) introduces a premature stop codon before the second in-frame ATG. As a consequence of either c.2T>G (p.M1_W32del) or c.96G>A (p.W32X), impaired translation from the first in-frame ATG results in a mild NPD-B phenotype instead of the severe phenotype expected for a complete deficiency of the enzyme, suggesting that when the first ATG is not functional, the second initiation codon (ATG33) still produces a fairly functional sphingomyelinase. Analysis of the patients'clinical and molecular data demonstrated that all five patients with the intermediate phenotype carried at least one severe mutation. No association between the onset of pulmonary symptoms and genotype was observed. Finally, the presence of c.96G>A (p.W32X), the most frequent allele among Italian NPD type B population, and c.1799G>C (p.R600P) as compound heterozygotes in association with severe mutations suggested a beneficial effect for both mutations.
Collapse
Affiliation(s)
- M G Pittis
- Unità di Malattie Metaboliche, I.R.C.C.S. Burlo Garofolo, Trieste, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Marçais C, Bernard S, Merlin M, Ulhmann M, Mestre B, Rochet-Mingret L, Revol A, Berthezene F, Moulin P. Severe hypertriglyceridaemia in Type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 deficiency. Diabetologia 2000; 43:1346-52. [PMID: 11126401 DOI: 10.1007/s001250051537] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
AIMS/HYPOTHESIS Hypertriglyceridaemia is common in Type II (non-insulin-dependent) diabetes mellitus. Only subgroups of patient however have type V hyperlipidaemia. To investigate the coordination between genetic factors in the modulation of hypertriglyceridaemia in Type II diabetes, we studied three major modifier loci: apoC-III (both Sst-I and insulin-responsive element polymorphisms), apolipoprotein E genotypes and lipoprotein-lipase mutations. METHODS We studied apoCIII gene polymorphisms, apolipoprotein E genotypes and lipoprotein-lipase gene mutations in 176 patients with Type II (non-insulin-dependent) diabetes mellitus, either normolipaemic (group N, n = 116), mildly hypertriglyceridaemic (group T, n = 28) or with a history of severe hypertriglyceridaemia (triglyceride > 15 g/l) (group H, n = 32). RESULTS Mild hypertriglyceridaemia in Type II diabetes did not associate with any gene variants in this study. Severe hypertriglyceridaemia was, however, associated with the presence of the apoC-III S2 allele (50% of the patients in group H compared with 15.5 % in group N, p < 0.0001). Additionally this particular phenotype was associated with a low prevalence of the apo E3 allele (35.9% in group H vs 18.1 % in group N, p < 0.005) and a statistically significant over-representation of the E2E4 genotypes. Inactivating lipoprotein-lipase mutations were found in four patients (three heterozygotes, one homozygote), none was found in group N or T. Thus 68.7 % of group H patients (22/32) (vs 21.4 % in group T, p < 0.0005) were carriers of either S2 allele, lipoprotein-lipase mutants or E2E4 genotype with most lipoprotein-lipase mutants or E2E4 genotypes or both in the non-carriers for the S2 allele (6/7). CONCLUSION/INTERPRETATION Our results strongly support the hypothesis that severe hyperlipaemia in Type II diabetes crucially depends on genetic factors which impair the clearance of triglyceride-rich lipoproteins.
Collapse
Affiliation(s)
- C Marçais
- CNRS UMR5014 Laboratory, Lyon-I University, France
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pruneta V, Pulcini T, Lalanne F, Marçais C, Berthezène F, Ponsin G, Moulin P. VLDL-bound lipoprotein lipase facilitates the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from HDL to VLDL. J Lipid Res 1999; 40:2333-9. [PMID: 10588959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
In recent years, it has been established that lipoprotein lipase (LPL) is partly associated with circulating lipoproteins. This report describes the effects of physiological amounts of very low density lipoprotein (VLDL)-bound LPL on the cholesteryl ester transfer protein (CETP)-mediated cholesteryl ester transfer (CET) from high density lipoprotein (HDL) to VLDL. Three patients with severe LPL deficiency exhibited a strong decrease in net mass CET that was more than 80% lower than that of common hypertriglyceridemic subjects. Recombination experiments showed that this was due to an abnormal behavior of the VLDL fraction. Replacement of the latter by normal VLDL totally normalized net mass CET. We therefore prepared VLDL containing controlled amounts of bound LPL that we used as CE acceptors in experiments involving unidirectional radioisotopic CET measurements. These were carried out either in the absence or in the presence of inhibitors of LPL lipolytic activity. When LPL-induced lipolysis was totally blocked, the stimulating effect of the enzyme on the CETP-dependent CET was only reduced by about 50%, showing that it did not entirely result from its lipolytic action. These data were dependent upon neither the type of LPL inhibitor (E600 or THL) nor the source of CETP (delipidated plasma or partially purified CETP). Thus, in addition to the well-known stimulating effect of LPL-dependent lipolysis on CET, our work demonstrates that physiological amounts of VLDL-bound LPL may facilitate CET through a mechanism partially independent of its lipolytic activity.
Collapse
Affiliation(s)
- V Pruneta
- Laboratoire de Métabolisme des Lipides, Centre Hospitalier Lyon-Sud, Lyon, France
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
The mutator (RER(+)) phenotype has been shown to be a mutational mechanism for tumour-suppressor-gene inactivation in colorectal cancer. A group of 60 prostate-carcinoma patients was studied to determine the frequency, intratumour distribution and timing of mutator phenotype in this cancer. Ten microsatellite loci were analyzed in 172 carcinoma foci (CF) and in 57 associated non-cancerous prostate tissues, including 31 areas of prostate intra-epithelial neoplasia (PIN) and 26 non-dysplastic areas with glandular hyperplasia (HP). We detected lesions with the RER(+) phenotype in 42% (25/60) of the prostate tumours. Clonal foci with RER(+) phenotype were detected at similar frequencies in pre-cancereous PIN (16%, 5/31) as in associated carcinoma foci (22%, 37/172), but were detected in only one of the 26 non-dysplastic prostate tissues studied (4%). Thus, clonal RER(+) foci were significantly more frequent in CF than in HP (p < 0.05). MI itself was significantly more frequent in CF (53%, p < 0.0001) and in PIN (35%, p < 0.05) than in HP (12%). Furthermore, 5 PIN harboured microsatellite mutations also detected in the associated cancer. Our overall results therefore strongly suggest that the mutator phenotype may occur as an early event in prostate tumorigenesis.
Collapse
Affiliation(s)
- S M Miet
- Laboratoire de Biochimie, Unité de Biochimie Génétique, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | | | | | | | | | | |
Collapse
|
11
|
Moyret-Lalle C, Marçais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995; 64:124-9. [PMID: 7542226 DOI: 10.1002/ijc.2910640209] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
To study the role of ras, p53 genes and HPV virus (16 and 18) in the development of prostate cancer, we analyzed tissue sections from 27 patients affected with carcinomas (stages A to D) and from 24 patients with adenomas. Mutations of H, K and N-ras and p53 (exons 2-9) were studied by SSCP and DNA sequencing. Accumulation of p53 protein was studied by immunohistochemistry on tissue sections. Tumors were also analyzed for the presence of HPV16 and -18 sequences by PCR and DNA hybridization with sequence-specific oligonucleotides. No mutation was found in the three ras genes studied, either in carcinomas or adenomas. By SSCP analysis we identified p53 mutations in only 2 of 19 carcinomas studied, both in exon 7. Immunohistochemical results strongly correlate with the SSCP results: p53 protein was positive in tumors with p53 mutation but not in others; 32% of studied adenomas had detectable HPV16 DNA, while 53% of carcinomas were HPV16+. Among these I presented a p53 mutation. No HPV18 E6 sequence could be detected. Our data show that in prostate tumors from France, mutations of p53 and ras are rare events but that these tumors display detectable HPV16 DNA at a high frequency. The low incidence of p53 mutation, associated to a significant proportion of tumors showing HPV16 DNA, could suggest that in prostate cancer HPV16 infection could participate in p53 inactivation by E6.
Collapse
Affiliation(s)
- C Moyret-Lalle
- Institut de Génétique Moléculaire de Montpellier, France
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Mazoyer S, Lalle P, Moyret-Lalle C, Marçais C, Schraub S, Frappaz D, Sobol H, Ozturk M. Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 1994; 9:1237-9. [PMID: 8134127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Codon 257 of the p53 gene is an extremely rare target for somatic mutations (accounting for only two of 1600 published mutations). We report here two constitutional mutations both affecting the second nucleotide of codon 257. A thymine to adenine transversion resulting in an amino acid change from leucine to glutamine was found in one proband who developed multiple independent malignant tumors (osteosarcoma, phyllodes tumor, soft-tissue sarcoma). Her mother died of early-onset breast cancer. In the other case, a deletion resulting in a frameshift in the C-terminal coding region of p53 was found in a woman who was diagnosed with breast cancer at age 34. This woman belongs to a family with features of Li-Fraumeni syndrome. In both cases, the p53 mutations identified in the proband was found in other members of the family. Codon 257, even if rarely mutated in somatic cells, may thus be an important target for germ-line mutations.
Collapse
Affiliation(s)
- S Mazoyer
- Laboratoire d'Oncologie Moléculaire--CJF INSERM 9302, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Unsal H, Yakicier C, Marçais C, Kew M, Volkmann M, Zentgraf H, Isselbacher KJ, Ozturk M. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994; 91:822-6. [PMID: 8290606 PMCID: PMC43041 DOI: 10.1073/pnas.91.2.822] [Citation(s) in RCA: 125] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
We studied 80 hepatocellular carcinomas from three continents for p53 gene (TP53) mutations and hepatitis B virus (HBV) sequences. p53 mutations were frequent in tumors from Mozambique but not in tumors from South Africa, China, and Germany. Independent of geographic origin, most tumors were positive for HBV sequences. X gene coding sequences of HBV were detected in 78% of tumors, whereas viral sequences in the surface antigen- and core antigen-encoding regions were present in less than 45% of tumors. These observations indicate that hepatocellular carcinomas are genetically heterogeneous. Mozambican-type of hepatocellular carcinomas are characterized by a high incidence of p53 mutations related to aflatoxins. In other tumors, the rarity of p53 mutations combined with the frequent presence of viral X gene coding sequences suggests a possible interference of HBV with the wild-type p53 function.
Collapse
Affiliation(s)
- H Unsal
- Massachusetts General Hospital Cancer Center, Charlestown 02129
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Ozturk M, Ponchel F, Puisieux A, Marçais C. [The p53 gene in human hepatocarcinogenesis]. Pathol Biol (Paris) 1993; 41:21. [PMID: 8316453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- M Ozturk
- Laboratoire d'Oncologie Moléculaire, Centre Léon-Bérard, Lyon, France
| | | | | | | |
Collapse
|